Santhera Pharmaceuticals Aktie
| 14,50CHF | -0,30CHF | -2,03% |
WKN DE: A3EJMQ / ISIN: CH1276028821
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 91 | 43 | 45 | 44 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,16 | -0,04 | 0,16 | 2,31 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 18 | 25 | 3 | 35 | 76 |
| Summe Anlagevermögen | 65 | 51 | 8 | 85 | 68 |
| Summe Aktiva | 89 | 91 | 64 | 110 | 152 |
Bilanz (in Mio. EUR) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 71 | 49 | 52 | 25 | 41 |
| Summe Fremdkapital | 95 | 90 | 107 | 50 | 125 |
| Summe Eigenkapital | -6 | 1 | -44 | 60 | 28 |
| Summe Passiva | 89 | 91 | 64 | 110 | 152 |
Adresse
| Hohenrainstrasse 24, 4133 Pratteln | |
| Telefon | +41 (61) 906-89-50 |
| Fax | +41 (61) 906-89-51 |
| Internet | http://www.santhera.com |
Management
|
Ana de Vera
Deputy Chief Marketing Officer & Head-Development |
|
Andreas Missy
Chief of Staff |
|
Bradley Carl Meyer
Director |
|
Catherine Isted
Chief Financial Officer |
|
Dario Eklund
Chief Executive Officer |
|
Geert Jan van Daal
Chief Commercial Officer |
|
Günther Metz
Head-Business Development |
|
Marc Schrader
Chief Technology Officer |
|
Neville Kodkani
Head-Global Marketing & Partner Management |
|
Oliver P. Kronenberg
Secretary, Chief Legal Officer & General Counsel |
|
Oliver Strub
Head-Compliance |
|
Otto Schwarz
Director |
|
Philipp Gutzwiller
Independent Director |
|
Sabine Pilot
Head-Clinical Development Operations |
|
Sarah Holmes-Klotz
Global Head-People & Culture |
|
Shabir Hasham
Executive Director & Chief Medical Officer |
|
Thomas Meier
Chairman |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
